This site is intended only for healthcare professionals residing in Singapore




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsMaterialsVideosLet’s connectLet's ConnectContact usPfizer medical information
AMSResist the ResistanceAct now. Act how?Strategy to prevent catastropheSurveil. SurvivePolicy for PurposeBacterial InfectionsBacterial basicsDetection and selectionKnow the negativeThe HAP/VAP recapDispel the MBLPinpoint the positiveGo-to guidelinesFungal InfectionsFungal factsFind the fungiPolice the yeastBehold the mouldFight the fungiViral InfectionsVerdict on virusesResourcesViral Infections



Resist the ResistanceAct now. Act how?Strategy to prevent catastropheSurveil. SurvivePolicy for Purpose
Surveil. Survive.


Effective surveillance is a critical part of antimicrobial stewardship. Collective efforts to monitor changes in pathogen resistance patterns and susceptibility can strengthen our understanding of how antimicrobial resistance is evolving, helping to prevent, control, and treat infections.1

Bodies around the world are seeking to establish a complete picture of emerging resistance through surveillance programs. The World Health Organization’s (WHO) GLASS (the Global Antimicrobial Resistance and Use Surveillance System) is one example.2,3 Since 2015 it has offered a standardized approach to the collection and interpretation of data, while monitoring antimicrobial use and resistance in humans, the food chain, and the environment.2,3


At Pfizer, we have one of the world’s largest AMR surveillance website platforms: ATLAS (Antimicrobial Testing Leadership and Surveillance).1,4

The ATLAS program was initiated in 2004. Our searchable, interactive mobile app and website launched in 2017 with almost 20 years of cumulative data on emerging pathogen resistance and sensitivity patterns from over 80 countries.1,4

ATLAS was highlighted by the 2020 and 2021 Access to Medicines Benchmark Reports on AMR, as Pfizer remains the only company to publicly share results and raw data on resistance patterns.1,5–6

In 2020, ATLAS further expanded with the integration of data from SENTRY, one of the longestrunning antimicrobial surveillance programs in the world – adding much-needed antifungal information.1,4

Explore the hub


Policy for purpose

Want to make meaningful change? Learn about policy objectives

Find out more
ATLAS, Antimicrobial Testing Leadership and Surveillance; WHO, World Health Organization.ReferencesPfizer. Antimicrobial surveillance. Available at: antimicrobial-surveillance. Accessed May 2023.World Health Organization. Global antimicrobial resistance and use surveillance system ( GLASS) report. 2022. Available at: Accessed May 2023.World Health Organization. Antimicrobial resistance. Available at: antimicrobial-resistance. Accessed May 2023.ATLAS. Dashboard. Available at: Atlas ( Accessed May 2023.Access to Medicine Foundation. Antimicrobial resistance benchmark 2020. Available at: https:// Accessed May 2023.Access to Medicine Foundation. Antimicrobial resistance benchmark 2021. Available at: https:// Accessed May 2023.
PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.

Copyright © 2024 Pfizer Limited. All rights reserved.